| Detailed information |
|---|
| CancerLivER ID | 2207 |
| Biomarker | NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) |
| Biomarker Name/Symbol (given in Publication) | NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-Inflammation Index) |
| Biomolecule | Neutrophils and lyphocytes (Others) |
| Subject | Human |
| Degree of Validity | Biomarker for HCC prognosis and validated on independent dataset |
| Experimental Condition | Normal vs HCC; associated with TNM stage, PST and survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | NLR and SII in patients associated with more advanced stages of HCC |
| Level of significance | p < 0.05 |
| Source | Blood |
| PMID | 29123264 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 1168 HCC patients cohort |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2018 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |